Merus NV (NASDAQ:MRUS) shares traded down 5.3% on Wednesday . The stock traded as low as $11.00 and last traded at $11.90. 647,698 shares changed hands during trading, an increase of 2,029% from the average session volume of 30,424 shares. The stock had previously closed at $12.56.
Several research analysts have recently weighed in on the company. Zacks Investment Research downgraded Merus from a “buy” rating to a “hold” rating in a research note on Friday, November 9th. BidaskClub downgraded Merus from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 1st. Finally, ValuEngine downgraded Merus from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.00.
The company has a market capitalization of $280.77 million, a P/E ratio of -2.77 and a beta of 1.04.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Morgan Stanley boosted its stake in Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after purchasing an additional 30,538 shares during the period. Aquilo Capital Management LLC boosted its stake in Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock worth $25,577,000 after purchasing an additional 44,799 shares during the period. Laurion Capital Management LP bought a new position in Merus in the 3rd quarter worth about $2,104,000. JPMorgan Chase & Co. boosted its stake in Merus by 33.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after purchasing an additional 4,476 shares during the period. Finally, Acadian Asset Management LLC bought a new position in Merus in the 3rd quarter worth about $537,000. Institutional investors and hedge funds own 53.62% of the company’s stock.
WARNING: This report was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/12/06/merus-mrus-stock-price-down-5-3.html.
Merus Company Profile (NASDAQ:MRUS)
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
See Also: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.